Law360, San Diego (November 29, 2011, 10:40 PM ET) -- A federal court on Tuesday unsealed two ex-Pfizer Inc. employees' qui tam suit alleging the drugmaker marketed anti-fungal medication Vfend for off-label use that put patients at risk and caused the submission of millions of dollars in claims to government programs in violation of the False Claims Act.
U.S. District Judge R. Barclay Surrick ordered the complaint, which was initially brought in December 2005 by former Pfizer senior marketing manager Catherine Brown and former senior product manager Bernard Vezeau, to be unsealed and served on Pfizer...
Unsealed FCA Suit Accuses Pfizer Of Off-Label Marketing
To view the full article, take a free trial now.
